Figure 4

Survival, recurrence and metastasis curve analysis by the Kaplan-Meier method. (A) Patients with intense netrin-1 expression had significantly shorter median survival time (76.624 months) than those with weak netrin-1 expression (117.981 months) through log-rank univariate analysis (n = 120, P < 0.01). (B) Patients with weak UNC5B expression had significantly shorter median survival time (96.881 months) than those with intense UNC5B expression (128.939 months) (P < 0.01). (C) Recurrence curve analysis indicated that the difference was not statistically significant with intense netrin-1 expression (74.463 months) and lower expression (79.505 months). (P > 0.01) (D) The difference was not statistically significant in more (84.47 months) and less (69.225 months) UNC5B expression by recurrence curve analysis. (P > 0.01) (E) Patients with intense netrin-1 expression had significantly shorter median metastasis time (100.836 months) than those with weak netrin-1 expression (124.946 months). (P < 0.01) (F) Patients with weak UNC5B expression had significantly shorter median metastasis time (71.243 months) than those with intense UNC5B expression (125.957 months). (P < 0.01)